1291  WAVE2 suppresses mTOR activation to maintain T cell homeostasis and prevent autoimmunity.

1290  Breaks in mitochondrial DNA cause leakage of mitochondrial RNA into the cytoplasm, enhancing immune surveillance and synergizing with nuclear DNA damage to mount a robust type-I interferon immune response.

1289  The inflammasome receptor AIM2 acts independently of the inflammasome to reduce autoimmunity and stabilize regulatory T cells.

1288  IL-17 controls central nervous system autoimmunity through the intestinal microbiome.

1287  Platelets release mitochondrial antigens in systemic lupus erythematosus.

1286  Incorporating TLR9-inhibitory sequences in the AAV vector genome inhibits immunogenicity and enhances transgene expression in multiple animal models.

1285  Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial.

1284  Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling.

1283  Engineered off-the-shelf therapeutic T cells resist host immune rejection.

1282  On-demand biomanufacturing of protective conjugate vaccines.

Free Images for Presentation: sunipix SUNIPIX